NEW YORK (Reuters)—U.S. biotech shares extended their recent downward spiral on Tuesday as concerns about drug pricing continued to plague the sector while disappointing news from Illumina and other companies added to selling pressure. The Nasdaq Biotechnology index, down 4%, has now fallen about 17% since just before Hillary Clinton, front-runner to be the Democratic nominee…
Articles by Natasha Yetman
Complex Patients More Likely to Switch from Medicare Advantage
NEW YORK (Reuters Health)—Medicare Advantage plans might not be meeting the needs of patients requiring the costliest and most complex levels of care, a new study suggests. Between 2010 and 2011, such patients were more likely to switch from Medicare Advantage plans to traditional Medicare, rather than vice versa, researchers found. The results suggest people…
Does Insomnia in Patients with Knee OA Affect Pain?
New research explores the correlation between insomnia and pain in patients with knee osteoarthritis (OA). After conducting a multimodal sleep study, researchers from Johns Hopkins University in Baltimore uncovered a combined effect between catastrophizing and disturbed sleep, resulting in increased pain sensitivity, specifically central sensitization, for knee OA…
Weight-Bearing Exercise Eases Knee Osteoarthritis, Temporarily
(Reuters Health)—A program of weight-bearing exercise reduces pain and improves joint function, at least for two to six months, for people with osteoarthritis, according to a review of previous trials. “We had a systematic review for Cochrane from 2008 and 2009, but there were much less articles,” said Dr. Martin Van der Esch, who coauthored…
USBJI’s Project 1000 to Foster a Community of Musculoskeletal Educators
Since its inception, the U.S. Bone and Joint Initiative (USBJI) has promoted excellence in medical education on the musculoskeletal system and diseases of the bones and joints. To meet this goal, the USBJI has embarked on a new effort called Project 1000. Project 1000 will identify 1,000 local champions of musculoskeletal education throughout the country,…
Patients with Psoriasis, Psoriatic Arthritis at Increased Risk of Migraine
NEW YORK (Reuters Health)—Psoriasis and psoriatic arthritis are associated with an increased risk of migraine, according to new research from Denmark. “The main finding of our study was a psoriasis severity-dependent increased risk of new-onset migraine, and patients with severe skin psoriasis and psoriatic arthritis appeared to have the highest risk,” Dr. Alexander Egeberg from…
Doctors Often Uncomfortable Soliciting Donations for Patients
NEW YORK (Reuters Health)—Many doctors are asked to seek donations from grateful patients after successful cancer treatment, but most physicians are uncomfortable with this idea and feel a conflict of interest, according to a new study. “There are ethical ways of seeking donations from patients who have the means and want to give back,” Dr….
Novartis Biosimilar Takes Aim at Amgen’s Enbrel
ZURICH (Reuters)—The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said on Friday. Enbrel, or etanercept as the drug is known generically, is a big prize since it was the world’s fifth-biggest selling medicine in 2014…
Drug Industry Must Address Image Problem over Prices
NEW YORK (Reuters)—Teva Pharmaceutical Industries Ltd’s research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the U.S. Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients’ treatment costs,…
Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
Patients with non-radiographic axSpA experience reduced mobility and quality of life. In this study, researchers investigated the effect of treatment for nr-axSpA every four weeks with SQ golimumab (GLM). Seventy-one percent of patients in the GLM group achieved ASAS 20 response at Week 16, compared with 40.0% in the control group…
- « Previous Page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- …
- 97
- Next Page »